Has Selecta found a way around gene therapy's delivery problem? Takeda puts down $1B-plus to find out

Nicole DeFeudis

Editor

While gene therapies were traditionally thought of as one-and-done treatments, scientists now see a benefit in redosing patients down the road. The only problem? Some …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Has Selecta found a way around gene therapy's delivery problem? Takeda puts down $1B-plus to find out

Nicole DeFeudis

Editor

Sign up to read this article for free.

Director Oligonucleotide R&D

Bachem

Bubendorf, BL, Switzerland

CBER's deputy director departs as staff shakeup continues

Bluebird bio to sell to investment funds after struggling to make money from gene therapies

FDA approves first drug to treat ultra-rare lipid storage disease

Eli Lilly stockpiles $548M of oral weight loss drug ahead of launch

FDA says Ozempic, Wegovy shortage is over

Trusted protection: Why the current meningococcal vaccination schedule shouldn’t change without strong evidence

Has Se­lec­ta found a way around gene ther­a­py's de­liv­ery prob­lem? Take­da puts down $1B-plus to find out

Editor

Sign up to read this article for free.

Bachem

Bubendorf, BL, Switzerland

Has Selecta found a way around gene therapy's delivery problem? Takeda puts down $1B-plus to find out